Motilal Oswal retains Radico Khaitan as preferred buy in Q1 FY27 review

Motilal Oswal cited premiumisation-led growth in retaining Radico Khaitan as a preferred Buy. Its review was more selective on Bajaj Housing Finance and Eris Lifesciences, despite healthy growth and margin resilience across covered companies.

— Source publishedThu, 30 Jul, 2026, 12:06 IST·First seen Thu, 30 Jul, 2026, 12:38 IST·Source NDTV Profit

What happened

Motilal Oswal’s Q1 FY27 review retained Radico Khaitan as a preferred Buy, citing premiumisation-led growth. The brokerage stayed selective on Bajaj Housing

Key facts

  • Bajaj Housing Finance AUM rose 24% year-on-year to nearly Rs 1.5 trillion
  • Bajaj Housing Finance disbursements increased 33%
  • Motilal Oswal target price for Bajaj Housing Finance: Rs 95

Why this matters

The brokerage’s selective stance highlights premium portfolio exposure and disciplined valuations as key considerations for partnerships or acquisitions in consumer brands.

What to watch

  • Quarterly volume growth and revenue share of Prestige and Above brands
  • Gross-margin movement versus ENA, glass, packaging, and marketing-cost inflation
  • State excise-policy changes, price approvals, and route-to-market disruption in key markets
  • Urban discretionary-demand indicators and premium-alcohol category growth
  • New premium launches, distribution additions, and traction in higher-margin segments
  • Consensus earnings revisions and changes in Radico Khaitan's valuation premium versus spirits peers
  • Radico Khaitan is likely to intensify distribution expansion for premium and luxury labels, particularly in higher-income urban markets and travel retail channels.
  • Management may maintain elevated brand-building and launch spending to protect premium-market share, accepting some near-term cost pressure for longer-term mix gains.
  • Other listed spirits companies may accelerate premium product launches, partnerships, and packaging upgrades as investor preference shifts toward premiumisation execution.
  • Brokerage coverage may become more polarized, with companies showing growth but limited valuation comfort facing restrained target-price upgrades.